CAR-T Therapy in Practice: Clinical and Manufacturing Challenges скачать в хорошем качестве

CAR-T Therapy in Practice: Clinical and Manufacturing Challenges

CART shows unprecedented clinical responses, however, the durability remains a challenge, but a rapid availability is necessary to bring a treatment alternative to patients. Dr. Christof is treating Multiple Myeloma patients with cell therapy. He shared that many conventional treatments are not so effective. Therefore, new therapeutic targets need to be developed. His group has developed the KarMMa (EMA approved), a B Cell Maturation Antigen (BCMA)-direct CAR-T Cell Therapy. It is known that an increase in BCMA levels is associated with disease progression and poorer outcomes, and it has become a prime target at the moment. It is specific for tumor cells and we can live without B cells. He shared the results of the first clinical trials, and it was shown a response of 82% with the highest cell numbers, and about a third of the patients had complete remission. Christof said: “These are very exciting response figures that are totally unprecedented in this have to treat population, and this explains our excitement to get involved with these highly complex agents”. However, after one year, many patients showed a decrease in response, therefore is not yet a cure, is still a work in progress. He shared also the practical difficulties involved in Cell therapy such as the cost of the treatment for the patients, logistics, and timing, especially related to manufacturing processes.